An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals

Figure 5

Kaplan-Meier progression-free survival and overall survival estimates. OS—overall survival, TTP—time to progression. The 6mPFS% was 21% (95% CI 2.7–39.5); the 6mOS% was 47.4% (95% CI 24.8–69.9). The median PFS was 10 weeks (95% CI 2–25); the median OS was 25 weeks (95% CI 17–32).